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Alternative or complementary therapies for several inflammatory disorders have gained considerable acceptability and 
popularity in recent years. The Arjuna tree, Terminalia arjuna Roxb. (Combretaceae) holds antidiarrheal and antioxidant 
potential useful in management of inflammatory gastro intestinal ailments. Here, we evaluated the possible effect of  
T. arjuna hydroalcoholic extract (TAHA) and traditional Ayurvedic formulation Arjunarishta (AA) for the treatment of 
inflammatory bowel disease (IBD) and colorectal cancer. The phytochemical profile of test materials was confirmed via 
investigation of total phenolic and flavanoid content and standardized by HPLC-PDA method. In vitro antioxidant activity 
was carried out using 2,2-diphenyl-1-picrylhydrazyl (DPPH) and ferric reducing ability of plasma (FRAP) assay. 
Antimicrobial potential was tested against clinical isolates of IBD patients (HM95, HM233, HM251, HM615). Cytotoxicity 
was determined against human colorectal adenocarcinoma cells (Caco2, COLO.205), whereas, cytocompatibility against 
normal rat intestinal epithelial (IEC-6) and mouse fibroblast cells (L929). Additionally, in vitro oxidative cell damage stress 
was estimated by lipid peroxidation biomarker. TAHA displayed higher antioxidant capacity as compared to AA formulation. 
Different sensitivities were observed against different study cell lines in dose dependant manner. Similarly, significant (P 
<0.05) enhanced malondialdehyde (MDA) concentrations in test materials and 5-FU treated colorectal adenocarcinoma cells 
was detected as compared to control cells. TAHA and AA exhibited antimicrobial activity against IBD associated clinical 
isolates. These findings provide biological evidence for therapeutic application of TAHA and AA in IBD and colorectal cancer 
treatment. 
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Terminalia arjuna Roxb., (Fam. Combretaceae) has 
been used traditionally in cardiovascular diseases and 
cancer treatment. In ayurvedic concept, it helps in 
metabolic homeostasis1. The T. arjuna bark has been 
used in traditional system of medicine for various 
health benefits2. It has pharmacological activities, such as 
hypolipidemic, hypercholesterolemic, antimutagenic, 
antibacterial and antioxidant3,4. The active constituents 
include triterpenoids, saponins, tannins, flavonoids, 
ellagic acid, gallic acid, oligomeric proanthocyanidins, 
phytosterols, magnesium, calcium, zinc and copper5. 
 
Arishtas are conventional Ayurvedic formulations 
with decoction of herbs. These liquid dosage forms 
have self-generated alcohol, which improves extraction 
efficacy of molecules soluble in alcohol and water, 
resulting in improved drug delivery. Arjunarishta (AA), 
an arishta formulation supports improvement of cardiac 
functions, appetite and balances immune response6. 
This formulation contains T. arjuna, Madhuca indica, 
Vitis vinifera and Woodfordia fruticosa7.  
 
Inflammatory Bowel Disease (IBD) comprises of 
chronic, relapsing, inflammatory disorders of 
gastrointestinal tract that includes ulcerative colitis 
(UC) and Crohn’s disease (CD)8. It is characterized by 
diarrhoea, rectal bleeding, the urgency to have bowel 
movements, stomach cramps, fever and weight loss9. 
Several people have been affected worldwide with 
rising incidence in developing countries. The overall 
IBD burden is growing in India, in view of latest report, 
India has a very high disease load globally10. It is 
known to be associated with a substantial increase in 
the threat of colorectal cancer (CRC), especially after 
8-10 years of active disease. UC is one of the best 
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clinically characterized examples of such correlation 
between inflammation and carcinogenesis11.  
A pathogenic variant of Escherichia coli termed as 
Adherent Invasive E. coli (AIEC) has been involved in 
IBD pathogenesis. It adheres or invades the intestinal 
cells and further replicates within epithelial cells and 
underlying mucosal macrophages12. Earlier In vitro 
studies on the activity of antibiotics and bovine 
lactoferrin against Crohn’s disease associated with 
AIEC have established their potential for termination 
of E. coli from the gastrointestinal tract of patients with 
Crohn’s disease13,14. 
Medicinal plants used in traditional system of 
medicine comprise of numerous constituents that can 
be used to treat various illnesses, infections and even 
chronic diseases including IBD, cancer, etc.15-19. We 
have reported earlier that T. arjuna hydroalcoholic 
extract (TAHA) administration relieved the disease 
activity in trinitrobenzenesulfonic acid (TNBS) 
induced colitis in rat model20. In the present study, we 
assessed the efficacy of standardized TAHA and AA 
for cytotoxicity and malondialdehyde (MDA) level. 
Furthermore, we studied their antibacterial potential 
against AIEC strain and other IBD associated bacterial 
isolates along with the antioxidant activity. 
 
Material and Methods 
 
Test materials 
Dried stem bark of T. arjuna was procured from 
KLE Society’s Ayurved Pharmacy, (collected in 
February 2015 from the Western Ghats, Belagavi 
region, Karnataka – India), and authenticatedfrom 
AYUSH approved ASU drug testing laboratory at Shri 
BM Kankanwadi Ayurveda Mahavidyalaya, Belagavi, 
Karnataka – India and assigned the voucher number 
CRF/645/2015). T. arjuna containing traditional 
ayurvedic formulation Arjunarishta (AA) was purchased 
from the local market. 
 
Preparation of plant extract and preliminary phytochemical 
analysis 
The dried bark of T. arjuna was powdered and 
extracted with ethanol: water (70:30 v/v) using cold 
maceration method in a conical flask. The extract was 
manually shaken every hour for initial six hours. 
Afterwards, it was kept in a shaker at 200 rpm. The 
extract was filtered and concentrated in a rotary 
evaporator at 40ºC followed by complete drying using 
a water bath. The yield of hydroalcoholic extract 
(expressed as percentage w/w) was 22.2%. The extract 
was stored in an air tight container at 20ºC until 
further analysis. The test materials were subjected to 
preliminary phytochemical screening following the 
standard methods21. 
 
Quantification of total phenolic content (TPC) and total 
flavonoid content (TFC) 
TPC was determined by the Folin-Ciocalteu reagent 
method22. Test materials/standard (0.5 mL) of different 
concentrations were mixed with 1N Folin-Ciocalteu 
reagent and 20% sodium carbonate. The tubes were 
vortexed and allowed to stand for 40 min at 20°C for 
colour development. The absorbance was read at 725 nm 
using spectrophotometer (UV-1800, Shimadzu, Japan) 
against blank. The total content of phenolic compounds 
was expressed in Tannic acid equivalents (TAE)/g of dry 
extract. 
TFC was analyzed using previously reported method23 
with suitable minor modifications. Briefly, 240 μL 
sample, sodium nitrite (50 mg/mL), aluminium chloride 
(100 mg/mL in methanol) were added and mixed. After  
5 min, 1M sodium hydroxide was added. The TFC was 
calculated from a calibration curve using Quercetin as 
standard (12.5-800 µg/mL) and expressed as (Quercetin 
equivalent) QE/g of dry extract. 
 
HPLC-PDA analysis: TAHA and AA 
The phytochemical profile of TAHA and AA was 
performed as per previously reported method with 
suitable modification in column and mobile phase 
gradient using polyphenolic standards — gallic acid, 
ellagic acid and quercetin by HPLC24-26. Concisely, 
prominence HPLC system (Shimadzu, Japan) 
equipped with the binary pump, autosampler, a column 
oven and a photodiode array detector (PDA) was used. 
Chromatographic separations were carried out using C-
18 analytical column (150X 4.6 mm, 5 mm particle size; 
Syncronis, Thermo Scientific, USA).  
 
Assessment of in vitro antioxidant activity  
 
2,2-diphenyl-1-picrylhydrazyl (DPPH) assay 
The free radical scavenging capability of each 
extract solution on DPPH radicals was investigated as 
reported previously27. Briefly, 4 mL of 0.1 mM DPPH 
in methanol was mixed with one mL of each of extract 
(solution at different concentrations, 200-6.25 µg/mL). 
These mixtures were incubated in a dark room for  
30 min, and the free radical scavenging ability was 
estimated by measuring the absorbance at 517 nm 
using a spectrophotometer.  
 
Ferric Reducing Antioxidant Power (FRAP) assay 
The capability to reduce ferric ions was estimated 
using the standard method described by Benzie and 
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Strain28. The working FRAP reagent was freshly 
prepared by adding 300 mM sodium acetate buffer  
(pH 3.6), 10.0 mM tripyridyl triazine (TPTZ) solution 
and 20.0 mM FeCl3.6H2O solution in a ratio of 10:1:1 
(v/v/v). Test materials (1.0 mg/mL) and standard 
FeSO4 (0.1-1.0 mM) were then mixed with 3 mL of 
FRAP reagent, and the reaction mixture was incubated 
at 37°C for 30 min followed by absorbance 
measurement at 593 nm. Calibration was carried out 
with a fresh working solution of FeSO4. The 
antioxidant capacity based on ability to reduce ferric 
ions of the sample was calculated from the linear 
calibration curve.  
 
Antibacterial activity 
Four clinical bacterial isolates, E. coli HM95 
(AIEC), E. coli HM615 (colonic mucosa associated. 
E.coli), E. coli HM233 and E. coli HM251 (colonic 
mucus associated patient strains) were received under 
Material Transfer Agreement with University of 
Liverpool, United Kingdom. The bacterial isolates 
were subcultured on MacConkey agar plates and 
incubated aerobically at 37ºC. The media were 
procured from HiMedia Laboratories, Mumbai, India. 
The antimicrobial activity of TAHA and AA was 
evaluated by agar well diffusion method and MIC was 
detected by broth dilution method as previously 
reported with minor modifications29. Ciprofloxacin 
was used as positive control. 
 
Determination of cytotoxicity and cytocompatibility 
Human colorectal adenocarcinoma cells (Caco2, 
COLO.205) and normal rat intestinal epithelial and 
mouse fibroblast cells (IEC-6 and L929) were obtained 
from National Centre for Cell Sciences, Pune-India. 
The cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with 2 mM L-glutamine,  
100 IU/mL penicillin, 100 µg/mL streptomycin, and 
supplemented with 10% FBS procured from Gibco Life 
Technologies, Bangalore-India. Viable cell suspension 
50 µL with a density of 1×105 cells/mL (determined by 
Trypan blue exclusion method) was seeded into each 
well in a 96-well micro titre plate and final volume made 
up to 150 µL with DMEM media. Test materials were 
diluted in DMEM media to obtain different concentrations. 
100 µL of TAHA and AA (400-6.25 µg/mL) and 
Standard drug 5-FU (100-1.562 µg/mL ) was added to 
the wells followed by incubation for 48 h in the 
presence of 5% CO2 at 37ºC into CO2 incubator. After 
the incubation period, 20 µL of MTT reagent (3 -(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide, 
5 mg/mL in PBS) procured from HiMedia laboratories, 
was added to each well following 4 h incubation in 
dark. The supernatant was removed without disturbing 
the precipitated Formazan crystals. Formed crystals 
were dissolved by addition of 100 µL of DMSO and 
optical density (OD) was calculated at a wavelength of  
492 nm. Cell-viability assays were conducted as per 
previously reported standard procedure30. The study 
was performed in triplicates, and percent cell viability 
was calculated using the equation 
Percent cell viability = 
𝑂𝐷 𝑜𝑓 𝑡𝑒𝑠𝑡 𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙
𝑂𝐷 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
 × 100 
 
Lipid peroxidation in cells 
IEC-6, L929, COLO.205, and Caco2 cells were 
plated into 12-well plates at a density of 1×107 cells/mL 
in complete medium. Pre-confluent cells were treated 
with test materials for 48 h. MDA, a marker of lipid 
peroxidation, was measured using an Oxiselect™ 
TBARS Assay Kit (Cell Biolabs, Inc, San Diego, CA, 
USA) following the manufacturer’s protocol. 
Spectrophotometric measurements were recorded on 
the microplate reader at 532 nm. The concentration of 
MDA in samples was calculated using MDA standards 
as reference. 
 
Data analysis 
All determinations were carried out in triplicate. The 
results have been presented in the form of Mean ± SD. 
Calculation of IC50 value was carried out using 
GraphPad Prism 7 for Windows. 
 
Results and Discussion 
 
Preliminary phytochemical screening 
The phytochemical evaluation of TAHA and AA 
directed the presence of therapeutically active 
phytoconstituents: proteins, steroids, flavonoids and 
tannins. Whereas, alkaloids were present in TAHA and 
found absent in AA. 
In agreement with the present study, directed 
phytochemicals in T. arjuna bark extract has been 
reported previously31. On the other hand, the absence 
of alkaloids in Arjunarishta formulation along with the 
presence of other phytochemicals are as per previous 
report32 supporting our finding. These phyto-
constituents are well reported to have antioxidant, 
antimicrobial, anticancer, and anti-inflammatory 
potential33. Phenolic compounds are established for 
redox properties, and it allows them to act as an 
antioxidant through their free radical scavenging 
ability. Therefore, total phenolic concentration could 
be used for quick screening of antioxidant 
potential16,19. The antioxidant potential of the test 
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materials was confirmed through DPPH and FRAP 
assay and TAHA expressed comparable results with 
standard gallic acid.  
 
Total phenolic/flavonoid content 
The TPC in test materials was estimated according 
to Folin-Ciocalteu method and expressed as TAE 
calculated from the calibration curve (R2 = 0.991). TPC 
was seven folds higher in TAHA (502.6 mg TAE/g) as 
compared to AA (79.53 mg TAE/g). TFC was 
calculated from the standard quercetin calibration 
curve (R2 = 0.994) was 488.25 and 62 mg QE/g in 
TAHA and AA, respectively. 
 
Phytochemical standardization – HPLC analysis 
The phytochemical standardization of TAHA and 
AA was performed using marker based approach. 
Gallic acid, ellagic acid and quercetin polyphenolic 
standards were utilized for standardization of TAHA 
and AA. The HPLC analysis findings depicted good 
resolution of peaks and the presence of polyphenolic 
markers in both test materials was recognised with the  
help of retention time (Rt) matching with equivalent to 
reference standards (Fig. 1 A and B). 
 
Antioxidant properties of TAHA and AA 
The antioxidant potential of the test materials was 
explored by DPPH and FRAP assay (Table 1). It was 
observed that TAHA showed better antioxidant activity 
compared to AA. The standard: Gallic acid indicated 
higher antioxidant potential as compared to TAHA in 
DPPH assay. However, TAHA displayed better 
antioxidant activity in comparison with Gallic acid 
using FRAP assay. 
 
Table 1 — Antioxidant activity of TAHA and AA 
Test materials  
DPPH activity  
(IC50 µg/mL) 
FRAP activity  
(mM Fe2+ /g) 
TAHA 51.31±1.23 1907.00±0.88a 
AA 1025.00±1.15a 290.00±1.22a 
Gallic acid 49.89±1.08 1643.00±1.37 
[Data are expressed as mean±SD of three individual determinations. 
The data were analysed using one-way ANOVA followed by 
Dunnett's multiple comparison test. Compared with standard-gallic 
acid, a P <0.05; DDPH: 2,2-diphenyl-1-picrylhydrazyl; FRAP: ferric 
reducing ability of plasma] 
 
 
 
 
Fig. 1 — HPLC chromatogram of (A) TAHA; and (B) AA with reference standards 
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Antibacterial activity 
The results of well diffusion assay and MIC values 
of TAHA and AA against the four IBD clinical isolates 
are listed in Tables 2 and 3, respectively. No inhibitory 
zone was detected for AA. Intestinal inflammation is a 
chronic condition that needs the administration of 
presently available drugs for extended duration and in 
several cases this can be linked with the onset of severe 
effects or non-compliance. This has stimulated the 
need for discovery of newer substances from natural 
origin, including medicinal plants as antimicrobial 
substances to attain efficacy and better tolerability. 
There is increasing evidence that the mucosa-
associated microbiota, may be essential in the 
pathogenesis of the inflammatory bowel diseases: 
ulcerative colitis, and Crohn’s Disease34. However,  
T. arjuna bark and Arjunarishta, antimicrobial activity 
against IBD isolates has not been reported till date. 
Although T. arjuna bark and leaves have been reported 
for its antimicrobial potential against Gram positive/ 
negative ear pathogens35 and broad-spectrum activity 
against diarrhea causing bacteria36. In addition, it is 
documented that ‘Bhoxa community’ of Dehradun 
district, Uttarakhand, India use this medicinal plant for 
treatment of dysentery and diarrhea37. T. arjuna 
showed a zone of inhibition against the test bacteria. 
Whereas, AA did not exhibit inhibition zone possibly 
could be owing to its inability to diffuse through media. 
These results support our earlier findings suggesting a 
beneficial role of TAHA in TNBS induced colitis20. 
 
In vitro anticancer and cytocompatibility assay 
Cytotoxicity assay resulted in reduction of percent 
cell viability when tested at concentrations ranging 
from 400-12.5 µg/mL for the test materials and  
5-fluorouracil (5-FU) from 100-1.562 µg/mL. The 
cytotoxicity was assessed by MTT assay on two human 
colorectal adenocarcinoma cells, COLO.205 and 
Caco2. The IC50 value was obtained to assess its 
inhibitory concentration that causes 50% cell viability. 
The test materials and 5-FU presented a concentration-
dependent deduction in percent cell viability after 48 h 
exposure (Table 4).  
Test materials and 5-FU were examined for 
cytocompatibility assay at similar concentrations 
against L929 (Mouse fibroblast cells) and IEC-6 (Rat 
intestinal cells) using colorimetric MTT assay. Test 
materials displayed good cytocompatibility against the 
study cell lines (Fig. 2 A and B). Similarly, 5-FU was 
also analyzed for cytocompatibility as per IC50 value 
(Fig. 2C). Cytotoxicity assessment is important to 
validate the anticancer potential of medicinal plants. 
Therefore, we evaluated the cytotoxic potential of  
T. arjuna on human colorectal adenocarcinoma cells. 
Its phytoconstituent: Arjunic acid has been found 
active against human oral, ovarian and liver cancer cell 
lines38. In addition, T. arjuna extracts are reported to be 
effective against N-nitrosodiethylamine induced 
hepatocellular carcinoma in rats acting through 
carbohydrate  metabolizing  enzymes39.  Similar dose  
 
Table 4 — Effect of TAHA, AA, and 5-FU treatment on COLO.205 and Caco2 cells. % cell viability of treated cells and  
IC50 values of test materials and standard drug 
Sample (µg/mL) 12.5 25 50 100 200 400 IC50 (µg/mL) 
TAHA 
COLO.205 98.82±0.36  97.81±0.30a 94.42±0.50a 51.76±1.06a 33.39±0.86a 30.74±1.72a 145.3±0.53 
Caco2 88.25±0.44a 73.03±0.31a 53.70±1.11a 48.77±0.38a 42.00±0.41a 37.00±1.99a 90.4±0.66 
AA 
COLO.205 97.49±2.61  97.13±3.25  94.31±0.06a 69.50±1.38a 40.63±1.01a  30.03±2.52a 183.6±1.19 
Caco2 87.67±0.48a 83.93±0.95a 70.11±0.96a 53.97±0.67a 47.79±0.98a 40.00±1.00a 182.9±0.21 
Sample (µg/mL) 3.12 6.25  12.5 25 50 100 IC50 (µg/mL) 
5-FU 
COLO.205 79.23±1.07a 68.00 ±1.27a 58.18±0.67a 50.63±0.88a 38.07±2.02a 31.14±1.03a 24.12±1.29 
Caco2 83.00±2.11a 76.00±1.59a 67.28±1.91a 55.18±1.09a 42.27±2.17a 30.34±1.67a 32.42±0.78 
[Data are expressed as mean ± SD of three individual experiments. The data were analysed using one-way analysis of variance 
(ANOVA) followed by Dunnett's multiple comparison test. Compared with control (considered as 100 %), a P <0.05] 
 
Table 2 — Antimicrobial activity by agar well diffusion method 
Microbial strains  
Zone of inhibition (mm) 
TAHA  
(50 mg/mL) 
TAHA  
(25 mg/mL) 
Ciprofloxacin  
HM95 (CD) 22.67±0.58 21.33±1.53 21.00±1.00 
HM233 (UC) 24.67±0.58 a 21.00±1.00a 27.00±1.00 
HM251 (UC) 24.00±1.00a 22.67±1.53a 29.67±0.53 
HM615 (CD) 24.33±0.58a 22.33 ±1.16a 20.33±0.58 
[Data are expressed as mean±SD of three individual determinations. 
The data were analysed using one-way ANOVA followed by 
Dunnett's multiple comparison test. Compared with standard-
ciprofloxacin for respective microbial strain, a P <0.05] 
 
Table 3 — Minimum Inhibitory Concentration (MIC) values of 
TAHA and AA 
Microbial 
strains 
TAHA 
(mg/mL) 
AA (%) 
Ciprofloxacin 
(µg/mL) 
HM95 (CD) 6.25 12.5 1.25 
HM233 (UC) 6.25 12.5 1.25 
HM251 (UC) 6.25 12.5 1.25 
HM615 (CD) 6.25 12.5 1.25 
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dependent cytotoxicity has been observed in our study 
against colorectal adenocarcinoma cells supporting its 
traditional use in cancer treatment40. 
 
Lipid peroxidation 
The levels of MDA content are shown in Table 5. 
TAHA and AA exposure indicated significant (P <0.05) 
enhanced lipid peroxidation in treated COLO.205 and 
Caco2 cells as compared to untreated control, which 
was concentration dependant. This increase 
demonstrates that both test materials amplified MDA 
production in carcinoma cells by 52 and 48% at 200 
µg/mL of TAHA exposure on COLO.205 and Caco2 
cells, respectively when compared to the control while 
AA exposure produced 25 and 26% at 200 µg/mL. 
Additionally, normal cells treated with 5-FU resulted 
in a significant (P <0.05) increase in MDA 
concentration as compared to its control.  
Oxidative stress creates one of the molecular 
mechanisms  by  which  bioactive  substances  induce  
cytotoxicity and apoptosis. To investigate the degree of 
oxidative cell damage in colorectal adenocarcinoma 
cells exposed to test materials and 5-FU, we carried out 
lipid peroxidation study. Our study findings indicated 
a significant rise in malondialdehyde (a by-product of 
lipid peroxidation and biomarker of oxidative stress) 
levels in TAHA and AA treated carcinoma cells as 
compared to control cells. Similarly, HepG2 cells 
exposed to T. arjuna extract directed induction of reactive 
oxygen species production and consequently causing 
apoptosis41. In addition, gallic acid present in T. arjuna 
is known to induce ROS induced cell death in human 
prostate cancer cells through its autoxidation42. Therefore, 
the present study demonstrated that both the test materials 
and standard drug increased the lipid peroxidation with 
a simultaneous decline in cell viability in colorectal 
cancer cell line with its mechanism of generation of 
oxidative stress-mediated apoptosis43.  
 
Conclusion 
Results of the present study suggest that the 
Terminalia arjuna hydroalcoholic extract (TAHA) 
exhibited comparable in vitro antioxidant activity with 
gallic acid. Whereas, Antibacterial potential of both the 
test materials was observed against the bacterial 
isolates from CD and UC patients used in the study. 
TAHA and AA exhibited cytotoxicity in the cell lines 
where the lipid peroxidation was enhanced after test 
material exposure, which could be due to malon-
dialdehyde formation associated cell death. However, 
further in vitro and in vivo investigations are required 
to understand precise mechanism.  
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